Previous 10 | Next 10 |
home / stock / glpgf / glpgf news
David Einhorn's 13F stock portfolio value increased from $1.49B to $1.75B this quarter. Greenlight increased Capri Holdings, ODP Group, Livanova, & Victoria’s Secret while reducing Twitter, Concentrix, & EchoStar. They also added Global Payments while dropping AerCap an...
Galapagos NV (GLPG) Q4 2021 Earnings Conference Call February 25, 2022 8:00 AM ET Company Participants Sofie Van Gijsel - Senior Director, Investor Relations Onno van de Stolpe - Chief Executive Officer Bart Filius - Chief Operating Officer Walid Abi-Saab - Chief Medical Officer Michele Manto...
Galapagos NV (GLPG) Q3 2021 Earnings Conference Call November 5, 2021 8:00 AM ET Company Participants Sofie Van Gijsel - Senior Director, Investor Relations Onno van de Stolpe - Chief Executive Officer Bart Filius - Chief Operating Officer Walid Abi-Saab - Chief Medical Officer Michele Manto ...
Galapagos NV (GLPG) Q2 2021 Earnings Conference Call August 6, 2021 08:00 AM ET Company Participants Sofie Van Gijsel - IR Onno van de Stolpe - CEO Dr. Walid Abi-Saab - CMO Bart Filius - COO and President Conference Call Participants Brian Abrahams - RBC Capital Markets Laura Sutcliffe - UBS ...
Galapagos has over $6.2 billion in cash with no debt and a market capitalization of only $4.5 billion. The company has an approved product that is expected to generate €500 million annually in sales in Europe in the medium term. The partnership with biotech giant Gilead dem...
Galapagos NV (GLPG) Q1 2021 Earnings Conference Call May 07, 2021 08:00 AM ET Company Participants Elizabeth Goodwin - VP of IR Onno Van De Stolpe - Co-Founder & CEO Bart Filius - President & COO Walid Abi-Saab - Chief Medical Officer Piet Wigerinck - Chief Scientific Officer Michele ...
Gilead's shares have come down a lot over the last year, once euphoria around Veklury passed. Gilead is well-positioned in HIV and several other markets. The company combines a low valuation with attractive dividend growth properties. For further details see: Gilead Scie...
The following slide deck was published by Galapagos NV in conjunction with this event. For further details see: Galapagos (GLPG) Investor Presentation - Slideshow
Galapagos NV (GLPG) Q4 2020 Earnings Conference Call February 19, 2021 8:00 AM ET Company Participants Elizabeth Goodwin - Vice President, Investor Relations Onno van de Stolpe - Chief Executive Officer Bart Filius - Chief Operating Officer & Chief Financial Officer Walid Abi-Saab - Chief...
The world is awash with liquidity as interest rates remain at historic lows. Cheap liquidity is the fuel that will spark the next buyout bing in smaller cap biotech. A diversified ETF specializing in smaller cap biotechs is the perfect vehicle to capitalize on the trend as detaile...
News, Short Squeeze, Breakout and More Instantly...
Galapagos Genomics Ord Company Name:
GLPGF Stock Symbol:
OTCMKTS Market:
Galapagos Genomics Ord Website:
Mechelen, Belgium; June 14, 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will present encouraging new data from the ongoing Phase 1/2 ATALANTA-1 study of CD19 CAR-T candidate, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma (R/R NHL) at the annual Euro...
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next generation MAGE-A4 TCR T-cell therapy) produced on Galapagos’ decentralized manufacturing platform in patients with head & neck cancer Uza-cel has shown enc...
BCA's national network of blood centers will provide decentralized manufacturing services for Galapagos' CAR-T product candidates, close to cancer treatment centers Collaboration enables rapid deployment of Galapagos' decentralized CAR-T platform across the U.S., improving patient access ...